Published in Gene Therapy Weekly, July 14th, 1997
Koushi Yamaguchi and colleagues from the Harvard Medical School, and Hybridon, Inc., Massachusetts, collaborated on a series of in vitro experiments designed to test the therapeutic utility of GEM 91 and its resistance profile ("The Multiple Inhibitory Mechanisms of GEM 91, a gag Antisense Phosphorothioate Oligonucleotide, for Human Immunodeficiency Virus Type 1," AIDS Research and Human Retroviruses, May 1, 1997;13(7):545-54).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.